HCV NEXT September/October Issue - Two Approvals Offer Even More Options for HCV Treatment

"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, practice management issues, to name a few.

The following articles appeared in the September/October edition of HCV NEXT, provided online at Healio.

Table of Contents

FDA approves Vosevi for HCV

Cover Story

HIV/HCV Coinfection Remains Marginalized Despite Progress

Editorial
Two Approvals Offer Even More Options for HCV Treatment
Ira M. Jacobson, MD

FDA News
FDA approves Mavyret, the first pan-genotypic 8-week treatment for HCV

In the Journals
SVR reduces hepatic venous pressure gradient, portal hypertension persists

Liver cancer, mortality risks decrease with SVR after direct-acting antivirals

In the Journals Plus
Liver cirrhosis a risk factor for treatment failure in HCV–HIV coinfection

Meeting News
Universal screening in Cherokee Nation aims to eliminate hepatitis C

Indigenous people bear ‘disproportionately high burden’ of hepatitis

Link - https://www.healio.com/hepatology/news/print/hcv-next